2024預見ASCO｜頭頸惡性良性腫瘤領域中國之聲一覽

前言

一年一度的惡性良性腫瘤界“奧斯卡”——2024年美國臨床惡性良性腫瘤學會（ASCO）年會将于當地時間5月31日-6月4日在美國芝加哥盛大召開，衆多國際重磅的臨床科研成果将在ASCO大會期間披露。本文将聚焦頭頸惡性良性腫瘤領域，一起“預見”那些有望改變臨床實踐的中國之聲！

Oral Abstract Session

摘要号：LBA6000

Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.

卡瑞利珠單抗輔助治療高危局部晚期鼻咽癌(DIPPER)：一項多中心、開放标簽、III期随機對照試驗

講者：劉需 中山大學惡性良性腫瘤防治中心

摘要号：6001

Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial.

替雷利珠單抗對比安慰劑聯合誘導化療序貫同步放化療，繼以替雷利珠單抗或安慰劑輔助治療局部晚期鼻咽癌：一項多中心、随機、安慰劑對照、雙盲、III期試驗的期中分析

講者：陳秋燕 中山大學惡性良性腫瘤防治中心

摘要号：6002

Endostar combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A phase III, prospective, randomised-controlled, multicenter clinical trial.

Endostar聯合同步放化療對比單純同步放化療應用于局部晚期咽癌(LA-NPC)的療效：一項III期、前瞻性、随機對照、多中心臨床試驗

講者：康敏 廣西醫科大學第一附屬醫院

Clinical Science Symposium

摘要号：6011

Neoadjuvant sintilimab and platinum-doublet chemotherapy followed by transoral robotic surgery for HPV-associated resectable oropharyngeal cancer: Single-arm, phase II trial.

信迪利單抗聯合含鉑雙藥化療新輔助治療經口機器人手術治療的HPV相關可切除口咽癌：單臂II期試驗

講者：宋明 中山大學惡性良性腫瘤防治中心

Rapid Oral Abstract Session

摘要号：6013

Preliminary results of phase I/II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in patients with EGFR positive solid tumors.

pucotenlimab聯合表皮生長因子受體-抗體藥物偶聯物(EGFR-ADC)MRG003治療EGFR陽性實體惡性良性腫瘤患者的I/II期研究初步結果

講者：阮丹雲 中山大學惡性良性腫瘤防治中心

摘要号：LBA6018

Covalent FAPI PET enables accurate management of medullary thyroid carcinoma: a prospective single-arm comparative clinical trial.

共價結合的FAPI PET可精準治療髓樣甲狀腺癌：一項前瞻性單臂比較性臨床試

講者：孔梓任 中國醫學科學院惡性良性腫瘤醫院

Poster Session

摘要号：6023

Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A prospective, single-arm, open-label, phase 2 study.

帕博利珠單抗聯合白蛋白結合型紫杉醇和鉑類藥物作為複發性或轉移性頭頸鱗癌（R/M HNSCC）患者的一線治療：一項前瞻性、單臂、開放标簽的II期研究

講者：桂琳 中國醫學科學院惡性良性腫瘤醫院

摘要号：6024

Efficacy of nimotuzumab added to concurrent chemoradiotherapy after induction chemotherapy for patients with locally advanced nasopharyngeal carcinoma.

在誘導化療後尼妥珠單抗與同步放化療聯合治療局部晚期鼻咽癌患者

講者：吳三綱 廈門大學附屬第一醫院

摘要号：6026

Safety and efficacy of iparomlimab and tuvonralimab in combination with gemcitabine and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase 2 trial (DUBHE-N-302).

DUBHE-N-302多中心、單臂、II期試驗：iparomlimab和tuvonralimab與吉西他濱和順鉑聯合作為複發性或轉移性鼻咽癌患者一線治療的療效和安全性

講者：黃岩 中山大學惡性良性腫瘤防治中心

摘要号：6027

The role and mechanism of circadian clock gene BMAL1 in the proliferation and metastasis of nasopharyngeal carcinoma by inhibition TGF-β1/Smads pathway.

BMAL1基因在抑制TGF-β1/Smads通路中對鼻咽癌增殖和轉移的作用和機制

講者：趙朝芬 貴州醫科大學附屬醫院

摘要号：6030

Identifying patients at high risk of recurrence by rebound of plasma Epstein-Barr virus DNA in nasopharyngeal carcinoma.

通過鼻咽癌患者血漿中Epstein-Barr病毒DNA的回升來識别高複發風險患者

講者：Qixian Zhang 複旦大學附屬惡性良性腫瘤醫院

摘要号：6033

Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study.

抗LAG-3抗體LBL-007與抗PD-1抗體替雷利珠單抗聯合應用，聯合或不聯合化療，用于晚期鼻咽癌和其他惡性惡性良性腫瘤患者的Ib/II期劑量遞增/擴充研究

講者：楊雲鵬 中山大學惡性良性腫瘤防治中心

摘要号：6039

Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC).

特瑞普利單抗與安慰劑聯合吉西他濱和順鉑作為複發性或轉移性鼻咽癌（r/m NPC）一線治療的四年總生存率随訪結果和動态EBV滴度分析

講者：陳秋燕 中山大學惡性良性腫瘤防治中心

摘要号：6040

Long-term outcomes of anlotinib and penpulimab combined with chemotherapy in the treatment of patients with metastatic nasopharyngeal carcinoma that failed definitive platinum-based chemoradiotherapy.

安羅替尼和派安普利單抗聯合化療在轉移性鼻咽癌患者中的長期療效：對于經典鉑類化療放療失敗的患者的治療結果

講者：黃爽 浙江省惡性良性腫瘤醫院

摘要号：6043

Associations of ctDNA clearance and pathological response after neoadjuvant treatment in patients with locally advanced oral cancer.

局部晚期口腔癌患者新輔助治療後的ctDNA清除和病理反應的關聯性

講者：鐘來平 複旦大學附屬華山醫院

摘要号：6044

An open-label, single-center phase II trial of cadonilimab (an anti-PD-1/CTLA-4 bispecific antibody) in combination with platinum-based dual-drug neoadjuvant chemotherapy for locally advanced, resectable head and neck squamous cell carcinoma.

一項開放标簽、單中心的II期試驗：卡度尼利單抗（一種抗PD-1/CTLA-4雙特異性抗體）與含鉑雙藥新輔助化療聯合應用于局部晚期可切除頭頸部鱗狀細胞癌患者

講者：Fei Cao 中山大學惡性良性腫瘤防治中心

摘要号：6045

Tislelizumab plus neoadjuvant chemotherapy and concurrent chemoradiotherapy versus neoadjuvant chemotherapy and concurrent chemoradiotherapy in local advanced nasopharyngeal carcinoma.

與新輔助化療和同步放化療相比，替雷利珠單抗聯合新輔助化療和同步放化療治療局部晚期鼻咽癌的療效

講者：羅海清 廣東醫科大學附屬醫院

摘要号：6046

Characterizing the impact of sarcopenia on treatment response and survival in previously treated recurrent or metastatic nasopharyngeal carcinoma: Insights from a secondary analysis of the KL-A167 randomized trial.

肌肉萎縮對既往經治複發轉移性鼻咽癌患者的治療反應和生存影響：來自KL-A167随機試驗的二次分析的認識

講者：劉哲然 四川大學華西醫院

摘要号：6070

Neoadjuvant tislelizumab plus chemotherapy followed by salvage surgery and adjuvant tislelizumab for recurrent head and neck squamous cell carcinoma after radiotherapy: A single-arm, phase II trial.

替雷利珠單抗聯合新輔助化療後進行挽救手術和輔助替雷利珠單抗治療放療後複發的頭頸部鱗狀細胞癌患者：一項單臂、II期試驗

講者：伍文傑 北京大學口腔醫院

摘要号：6071

A prospective multicenter trial of dose escalation for weekly gemcitabine concurrent with intensity-modulated radiotherapy following cisplatin and gemcitabine induction chemotherapy in patients with locally advanced nasopharyngeal carcinoma.

一項前瞻性多中心試驗：在局部晚期鼻咽癌患者中，順鉑和吉西他濱誘導化療後，每周吉西他濱與調強放射治療同時進行劑量遞增的治療

講者：Zeng Qi 中山大學附屬第五醫院

摘要号：6072

Induction-concurrent versus concurrent-adjuvant chemoradiotherapy in patients with high-risk N2–3 nasopharyngeal carcinoma: An open-label, randomised, controlled, phase 3 trial.

高危N2-3鼻咽癌患者誘導-同步對比同步-輔助放化療：一項開放标簽、随機對照的III期試驗

講者：陳秋燕 中山大學惡性良性腫瘤防治中心

摘要号：6073

Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): An open-label, single-arm, phase 2 study.

新輔助替雷利珠單抗聯合阿法替尼治療局部晚期頭頸部鱗狀細胞癌（neoCHANCE-1）：一項開放标簽、單臂、II期研究

講者：衛治功 四川大學華西醫院

摘要号：6074

Analysis of PD-L1 expression in locally advanced head and neck squamous cell carcinoma and its correlation with the efficacy of neoadjuvant immunotherapy + chemotherapy: A retrospective real-world study.

局部晚期頭頸部鱗狀細胞癌中PD-L1表達的分析及其與新輔助免疫治療+化療療效的相關性：一項回顧性真實世界研究

講者：譚浩蕾 中南大學湘雅醫學院附屬惡性良性腫瘤醫院

摘要号：6075

Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase 3 trial.

順序放化療對比誘導化療加同步放化療治療區域局部晚期鼻咽癌的多中心、開放标簽、非劣效性、随機、III期試驗

講者：胡超蘇 複旦大學附屬惡性良性腫瘤醫院

摘要号：6078

Neoadjuvant immunochemotherapy for locally advanced hypopharyngeal squamous cell carcinoma: Pooled results analysis from two prospective single-arm phase 2 trials.

新輔助免疫化療治療局部晚期下咽鱗狀細胞癌：來自兩個前瞻性單臂II期試驗的彙總結果分析

講者：桂琳 中國醫學科學院惡性良性腫瘤醫院

摘要号：6080

Nivolumab combined with radical chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): An investigator-initiated, open-label, multicenter, single-arm, phase II clinical trial.

納武利尤單抗與放化療（避免同時使用順鉑）聯合治療高危局部區域晚期鼻咽癌（PLATINUM）：一項由研究者發起的、開放标簽、多中心、單臂、II期臨床試驗

講者：Cheng Xu 中山大學惡性良性腫瘤防治中心

摘要号：6084

Neoadjuvant and adjuvant toripalimab for high-risk locoregionally advanced nasopharyngeal carcinoma: A randomized, double-blind, placebo-controlled phase 2 trial.

特瑞普利單抗新輔助和輔助治療高危局部晚期鼻咽癌：一項随機、雙盲、安慰劑對照的II期臨床試驗

講者：劉賽蘭 中山大學惡性良性腫瘤防治中心

摘要号：6085

MR radiomics and neoadjuvant chemo-responsiveness with insights into selective treatment de-intensification in HPV-positive oropharyngeal carcinoma.

MR放射組學和新輔助化療反應性，對HPV陽性口咽癌中選擇性治療降低強度的認識

講者：Xueguan Lu

摘要号：6086

Induction chemotherapy followed by concurrent chemoradiotherapy combined with toripalimab and Endostar in high-risk locally advanced nasopharyngeal carcinoma: A multicenter, randomized, phase 2 trial.

誘導化療後同步放化療聯合特瑞普利單抗和恩度治療高危局部晚期鼻咽癌患者：一項多中心、随機、II期臨床試驗

講者：康敏 廣西醫科大學第一附屬醫院

摘要号：6090

Neoadjuvant immunochemotherapy and new radiomic predictor for resectable locally advanced oral squamous cell carcinoma.

可切除局部晚期口腔鱗狀細胞癌的新輔助免疫化療和放射組學預測因子

講者：劉磊 四川大學華西醫院

摘要号：6094

Clinical and genomic characterization of sporadic medullary thyroid carcinoma in Chinese patients.

中國患者散發性髓樣甲狀腺癌的臨床和基因組特征描述

講者：Yang Liu

摘要号：6099

Survival outcomes of concurrent radiotherapy and toripalimab versus radiotherapy alone for elderly patients with postoperative head and neck squamous cell carcinoma unfit for cisplatin.

不适合使用順鉑的老年頭頸部鱗狀細胞癌術後患者，接受同步放療聯合特瑞普利單抗與僅放療的生存結果

講者：窦聖金 上海交通大學附屬第九人民醫院

摘要号：6103

Efficacy and safety of anlotinib combined with sintilizumab in locally advanced or metastatic anaplastic thyroid carcinoma.

安羅替尼聯合信迪利單抗治療局部晚期或轉移性間變性甲狀腺癌的療效和安全性

講者：Haohua Zhu 中國醫學科學院惡性良性腫瘤醫院

摘要号：6105

The efficacy and safety of ulinastatin in the prevention and treatment of radiotherapy-induced oral mucositis in locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A multicenter, open-label, randomized controlled clinical trial.

ulinastatin在預防和治療放療引起的局部區域晚期鼻咽癌（LA-NPC）口腔黏膜炎的療效和安全性：一項多中心、開放标簽、随機對照臨床試驗

講者：王琳 中山大學惡性良性腫瘤防治中心

摘要号：6108

Pyrotinib in HER2-altered advanced salivary gland carcinomas: Analysis of two cohorts from an exploratory study.

吡咯替尼在HER2突變的晚期唾液腺癌中的應用：來自一項探索性研究的兩個隊列的分析

講者：窦聖金 上海交通大學附屬第九人民醫院

摘要号：6110

A non-invasive cfDNA fragmentomics assay for differentiating malignant and benign thyroid nodules.

一種非侵入性的循環遊離DNA片段組學檢測方法，用于區分惡性和良性甲狀腺結節

講者：單臻 中山大學第一附屬醫院

摘要号：TPS6123

EFFECT-neo: A phase 3 study of pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy in patients with resectable locally advanced head and neck squamous cell carcinoma.

III期EFFECT-neo研究：帕博利珠單抗聯合化療對比化療作為可切除局部晚期頭頸部鱗狀細胞癌的新輔助治療的療效

講者：張洋 北京同仁醫院

摘要号：TPS6129

Neoadjuvant adebrelimab plus dalpiciclib in HPV-negative locally advanced head and neck squamous cell carcinoma: A phase II clinical trial.

阿得貝利單抗聯合達爾西利新輔助治療非HPV相關局部晚期頭頸部鱗狀細胞癌：一項II期臨床試驗

講者：劉磊 四川大學華西醫院

編輯：Faline

審校：Faline

排版：KIKI

執行：Uni

醫脈通是專業的線上醫生平台，“感覺世界醫學脈搏，助力中國臨床決策”是平台的使命。醫脈通旗下擁有「臨床指南」「用藥參考」「醫學文獻王」「醫知源」「e研通」「e脈播」等系列産品，全面滿足醫學工作者臨床決策、擷取新知及提升科研效率等方面的需求。

本平台旨在為醫療衛生專業人士傳遞更多醫學資訊。本平台釋出的内容，不能以任何方式取代專業的醫療指導，也不應被視為診療建議。如該等資訊被用于了解醫學資訊以外的目的，本平台不承擔相關責任。本平台對釋出的内容，并不代表同意其描述和觀點。若涉及版權問題，煩請權利人與我們聯系，我們将盡快處理。